The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.
 
Rina Hui
Honoraria - Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Roche
 
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
 
Tamer M. Fouad
Employment - Eisai
 
Doreen Flaim
Employment - Merck
 
Lina Yin
Employment - Merck
 
Thao Dang
Employment - Merck
 
Roy S. Herbst
Leadership - Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; AstraZeneca; Biodesix; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Heat Biologics; Infinity Pharmaceuticals; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Nektar; Neon Therapeutics; NextCure; Novartis; Pfizer; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; Symphogen; TESARO
Research Funding - AstraZeneca; Lilly; Merck